OSE Immunotherapeutics SA (OSE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Vétoquinol SA

OSE Immunotherapeutics SA

Ipsen SA

Sanofi

Cellectis SA

Sensorion SA

Genfit SA

DBV Technologies SA

MedinCell SA

Innate Pharma SA

PHAXIAM Therapeutics SA

Why is OSE Immunotherapeutics SA ?

Flat results in Dec 24

OPERATING PROFIT(Q) Lowest at EUR -19.49 MM
PRE-TAX PROFIT(Q) Lowest at EUR -21.34 MM
NET PROFIT(Q) Lowest at EUR -18.49 MM

With ROE of 62.49%, it has a Very Attractive valuation with a 2.33 Price to Book Value

Over the past year, while the stock has generated a return of -39.46%, its profits have risen by 262.7% ; the PEG ratio of the company is 0

Below par performance in long term as well as near term

Along with generating -39.46% returns in the last 1 year, the stock has also underperformed France CAC 40 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to OSE Immunotherapeutics SA should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is OSE Immunotherapeutics SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

OSE Immunotherapeutics SA

-39.46%

-0.62

51.95%

France CAC 40

8.73%

0.52

16.76%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-32.91%

EBIT Growth (5y)

-205.15%

EBIT to Interest (avg)

-13.03

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.25

Sales to Capital Employed (avg)

0.27

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

10.46%

ROE (avg)

12.50%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.33

EV to EBIT

5.30

EV to EBITDA

4.68

EV to Capital Employed

2.77

EV to Sales

1.90

PEG Ratio

0.01

Dividend Yield

ROCE (Latest)

52.28%

ROE (Latest)

62.49%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for OSE Immunotherapeutics SA

Operating Cash Flow

Highest at EUR 28.2 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (EUR MM)

Debtors Turnover Ratio

Highest at 7.95%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for OSE Immunotherapeutics SA

Operating Profit

Lowest at EUR -19.49 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (EUR MM)

Pre-Tax Profit

Lowest at EUR -21.34 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (EUR MM)

Pre-Tax Profit

Fallen at -54.23%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (EUR MM)

Net Profit

Lowest at EUR -18.49 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (EUR MM)

Net Profit

Fallen at -78.41%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (EUR MM)

EPS

Lowest at EUR -0.9

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (EUR)